Group 1 - Johnson & Johnson is preparing for a potential sale of its orthopedics unit, DePuy Synthes, as part of its plan to separate the business, targeting completion within 18 to 24 months [1] - The company acquired DePuy Synthes in 2011 for $21.3 billion and aims to enhance strategic and operational focus through this separation [1] - Bank of America analysts believe that the exit makes sense and that DePuy Synthes could benefit from improved focus and competitiveness [3] Group 2 - The unit is estimated to be worth about $20 billion, or $28 billion including debt, with interest from buyout firms and potential strategic medical device players [3][5] - Johnson & Johnson is preparing financial materials for meetings with potential buyers in the coming weeks, with several large private equity firms considering joint bids [4] - DePuy Synthes generated $9.3 billion in annual sales, producing hip and knee replacement devices, which may attract further interest [5] Group 3 - Johnson & Johnson reported a fourth-quarter 2025 adjusted earnings of $2.46 per share, a 20.6% increase year over year, surpassing the consensus estimate of $2.44 [6] - The company expects 2026 sales to be between $99.50 billion and $100.5 billion, compared to the consensus of $98.89 billion [6]

Oxford, UK – 24 February 2026  –   Amber Therapeutics today announced a series of updates to its business highlighting the significant progress it has made since closing its $100 million (£80 million) Series A financing in July 2024—one of the largest Series A rounds ever raised by a European medical technology company. New appointees to Board and Leadership team bring global strategic, operational and commercial experience from across the medical device sector.New headquarters and state-of-the-art manufact ...

Company Overview - Electromed (ELMD) is a small medical device company based in Minnesota, founded in 1992 by Robert D. Hansen and Craig N. Hansen, and it went public in 2010 at a share price of $4 [1]. Investment Philosophy - The investment philosophy emphasizes the importance of compounding, dividend reinvesting, and patient investing through various market conditions to achieve wealth accumulation [1]. - The approach combines steady investment in high-quality assets with high-risk/high-reward opportunities, underappreciated turnaround plays, and transformative technologies [1]. Personal Background of the Analyst - The analyst has over 25 years of investment experience and has been teaching at the college/university level for over 20 years, holding a PhD from Brunel University [1]. - The analyst identifies as an amateur investor, self-taught without formal education in investing or business, and values learning from others [1].

On February 19, Joseph Stiglitz, the Nobel Prize-winning economist and ‘The Road to Freedom’ author, joined CNBC’s ‘Squawk Box’ to discuss the state of the economy and argued that conditions are poor and likely to deteriorate. Challenging more optimistic views, Stiglitz addressed the debate over why tariffs have not sparked an immediate inflationary explosion. He explained that economists must consider the counterfactual: what inflation would have been without the tariffs. He noted that while inflation was ...

Profitability improved as the company delivered its first full year of positive Adjusted EBITDA. Gross margin was 79% in the fourth quarter and 79.6% for the full year, with Maheshwari noting the full-year gross margin came in about 200 basis points above the company’s original 2025 guidance. He attributed the outperformance to stable average selling prices from favorable procedure mix and to operational initiatives such as supply chain efficiency and cost optimization.For the full year 2025, worldwide reve ...

SI-BONE Corporate Overview Recent Highlights – Record Performance Fourth Quarter 2025 Fiscal Year 2025 Note: Financial As of February 18, 2026 February 2026 Forward-Looking Statements The statements in this presentation regarding expectations of future events or results, including SI-BONE's expectations of continued revenue and procedure growth and financial outlook, are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve signific ...

Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced it has signed a distribution agreement with SI-BONE, focused on their innovative iFuse TORQ portfolio. This collaboration expands the Smith+Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and strengthens our position in high-frequency ...

VALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced Cary Vance, Interim CEO, and David O’Toole, CFO, will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. AVITA Medical management is scheduled to participate in a presentation and fireside chat on Wednesday, March 4, at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time. A ...

Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons are to the prior ...

CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 2026 Canaccord Genuity Musculoskeletal Conference on March 2, 2026 at 11:30 AM CST in New Orleans, LA.   A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://event.summitcast.com/view/d69xRqMspwymhwGUDdQoes/JC9qqvWhWggYawxGnDNtmz Abo ...